Monroe Dougald M
Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599-7035, USA.
Thromb Res. 2008;122 Suppl 1:S7-S10. doi: 10.1016/S0049-3848(08)70010-0.
Dilutional coagulopathy is observed in patients who have lost blood and had the blood volume replaced with components that do not have plasma procoagulants and anticoagulants. Since both procoagulant and anticoagulant mechanisms contribute to total thrombin generation, it is not clear whether the procoagulant or anticoagulant effects will dominate when both are decreased. Decreasing antithrombin levels leads to increasing thrombin generation in ex vivo models. However, in these same models decreasing prothrombin leads to decreasing thrombin generation. Previous studies can be extrapolated to suggest that the ratio of procoagulants and anticoagulants may be the critical component in determining thrombin generation. Limited clinical data suggest that factor VIIa has been useful in controlling intractable bleeding in some cases of dilutional coagulopathy. Preliminary data suggest that factor VIIa activation of factors X and IX on activated platelets enhances thrombin generation significantly in a model of dilutional coagulopathy. This may suggest a mechanism to account for the efficacy of factor VIIa in reducing blood loss in some settings of dilutional coagulopathy.
在失血患者中观察到稀释性凝血病,这些患者的血容量通过不含血浆促凝剂和抗凝剂的成分进行补充。由于促凝和抗凝机制均对总凝血酶生成有影响,因此当两者均降低时,促凝或抗凝作用何者占主导尚不清楚。在体外模型中,抗凝血酶水平降低会导致凝血酶生成增加。然而,在这些相同的模型中,凝血酶原降低会导致凝血酶生成减少。以往的研究可以推断,促凝剂和抗凝剂的比例可能是决定凝血酶生成的关键因素。有限的临床数据表明,在某些稀释性凝血病病例中,凝血因子VIIa有助于控制难治性出血。初步数据表明,在稀释性凝血病模型中,凝血因子VIIa激活活化血小板上的因子X和因子IX可显著增强凝血酶生成。这可能提示了一种机制,可解释凝血因子VIIa在某些稀释性凝血病情况下减少失血的疗效。